Analysts expect Aduro Biotech, Inc. (NASDAQ:ADRO) to report $4.32 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Aduro Biotech’s earnings, with the lowest sales estimate coming in at $3.70 million and the highest estimate coming in at $6.05 million. Aduro Biotech reported sales of $3.88 million during the same quarter last year, which indicates a positive year over year growth rate of 11.3%. The firm is scheduled to announce its next earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Aduro Biotech will report full-year sales of $4.32 million for the current fiscal year, with estimates ranging from $17.19 million to $19.50 million. For the next financial year, analysts anticipate that the firm will report sales of $33.03 million per share, with estimates ranging from $15.02 million to $74.82 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Aduro Biotech.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). The company had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.04 million. Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.54) EPS.
Several equities research analysts have recently commented on the company. HC Wainwright set a $18.00 price objective on Aduro Biotech and gave the company a “buy” rating in a report on Wednesday, November 1st. Oppenheimer Holdings, Inc. assumed coverage on Aduro Biotech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Aduro Biotech in a report on Monday, October 2nd. BidaskClub raised Aduro Biotech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Cowen and Company initiated coverage on Aduro Biotech in a report on Tuesday, July 18th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $19.14.
In related news, CEO Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $10.78, for a total value of $431,200.00. Following the transaction, the chief executive officer now owns 213,921 shares in the company, valued at $2,306,068.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Blaine Templeman sold 3,557 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total value of $39,091.43. Following the completion of the transaction, the vice president now owns 65,275 shares in the company, valued at approximately $717,372.25. The disclosure for this sale can be found here. Insiders have sold a total of 217,637 shares of company stock worth $2,132,780 in the last quarter. Company insiders own 6.60% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Allianz Asset Management GmbH bought a new position in shares of Aduro Biotech in the third quarter worth $516,000. Schwab Charles Investment Management Inc. increased its position in shares of Aduro Biotech by 5.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 174,478 shares of the biotechnology company’s stock worth $1,859,000 after purchasing an additional 9,140 shares during the period. Wells Fargo & Company MN increased its position in shares of Aduro Biotech by 111.5% in the third quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock worth $776,000 after purchasing an additional 38,415 shares during the period. Harvard Management Co. Inc. bought a new position in shares of Aduro Biotech in the third quarter worth $69,418,000. Finally, Trexquant Investment LP bought a new position in shares of Aduro Biotech in the third quarter worth $175,000. Institutional investors own 33.63% of the company’s stock.
Aduro Biotech (NASDAQ:ADRO) traded up $0.30 during midday trading on Friday, hitting $8.25. The stock had a trading volume of 824,100 shares, compared to its average volume of 402,670. Aduro Biotech has a 12 month low of $6.01 and a 12 month high of $15.52.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.